The concentrations of sOX40L were dozens of times higher than those of sOX40, and the expression of OX40L on CD19+ B cells and CD14+ monocytes was negatively correlated with disease duration in patients with relapsing MG. This evidence concerns the gene CD19 and myasthenia gravis.